3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma

Inclusion Criteria

• •Histologically or cytologically confirmed advanced solid tumors or lymphoma
• •* Disease considered incurable using standard treatment
• •ECOG performance status ≤ 2
• •Life expectancy \> 12 weeks
• •WBC ≥ 3,000/mm\^3
• •Absolute neutrophil count ≥ 1,500/mm\^3
• •Platelet count ≥ 100,000/mm\^3
• •Total bilirubin normal
• •AST/ALT ≤ 2.5 times upper limit of normal
• •Creatinine normal OR creatinine clearance ≥ 60 mL/min
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception prior to and during study treatment
• •No history of allergic reactions attributed to compounds of similar chemical or biologic composition to 3-AP (Triapine®) and/or gemcitabine hydrochloride
• •No known glucose-6-phosphate dehydrogenase (G6PD) deficiency
• •No uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situation that would limit compliance with study requirements
• •No pulmonary disease (e.g., dyspnea at rest, supplemental oxygen requirement, or baseline oxygen saturation \< 92%)
• •Prior gemcitabine hydrochloride allowed if given as a standard 30-minute infusion
• •* At least 4 weeks since prior gemcitabine hydrochloride
• •Patient may have received \< 2 lines of chemotherapy in the metastatic setting
• •No prior 3-AP (Triapine®) or fixed-dose gemcitabine hydrochloride
• •At least 6 weeks since prior nitrosoureas or mitomycin C
• •More than 3 weeks since prior radiotherapy
• •No other concurrent investigational agents
• •No concurrent combination antiretroviral therapy in HIV-positive patients
• •No other concurrent anticancer agents or therapies